Özge has a MSc. in Molecular Genetics from the University of Leicester and a PhD in Developmental Biology from Queen Mary University of London. She worked as a Post-doctoral Research Associate at the University of Leicester for six years in the field of Behavioural Neurology before moving into science communication. She worked as the Research Communication Officer at a London based charity for almost two years.
Switching from Gilenya (fingolimod) to Lemtrada (alemtuzumab) triggers significant and unexpected disease activity in some patients with multiple sclerosis (MS), according to a study published in ... Read more
A new study suggests a strong association in multiple sclerosis (MS) patients between high levels of fatigue and mental health, quality of life (QoL), and the ... Read more
Pin It on Pinterest